Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1188

Sort by

Sort Order Select

Journal Articles

Kinase inhibitors in CLL: drawing the roadmap

Nathan Fowler

Blood (2021) 137 (20): 2717–2719.

https://doi.org/10.1182/blood.2020010052

Published: 2021

Journal Articles

Targeting Critical Kinases and Anti-Apoptotic Molecules Overcomes Steroid Resistance in Infant MLL-Rearranged Leukemia

Anne Pieta De Groot, Yoriko Saito, MD, Eiryo Kawakami, Mari Hashimoto, Yuki Aoki, Rintaro Ono, MD PhD, Ikuko Ogahara, Saera Fujiki, Akiko Kaneko, Takashi Watanabe, PhD, Masatoshi Takagi, MD PhD, Daisuke Tomizawa, MD PhD, Katsuyoshi Koh, MD, Mariko Eguchi, MD, Eiichi Ishii, MD PhD, Osamu Ohara, Leonard Shultz, PhD, Shuki Mizutani, Fumihiko Ishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 3885.

https://doi.org/10.1182/blood-2019-129719

Published: 2019

Journal Articles

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A. Strickland, MD, Roland B. Walter, MD PhD MS, Ilaria Valimberti, Alessia Tagliavini, Paolo Mazzei, Caterina Fiesoli, Simona Scartoni, Daniela Bellarosa, Monica Binaschi, PhD, Pawel Chrom, MD PhD, Simone Baldini, MD, Krzysztof Brzózka, PhD, Angela Capriati, Andrea Pellacani, PhD MD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 3920.

https://doi.org/10.1182/blood-2019-125878

Published: 2019

Journal Articles

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Dirk Reinhardt, MD, Christian Michel Zwaan, Albert Hoenekopp, Julie Niolat, Sophie Ifrah, Florence Noel-Baron, Franco Locatelli, MD

Blood (2019) 134 (Supplement_1): 3835.

https://doi.org/10.1182/blood-2019-128043

Published: 2019

Journal Articles

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Blood (2019) 134 (Supplement_1): 3943.

https://doi.org/10.1182/blood-2019-128683

Published: 2019

Journal Articles

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Philipp Bernhard Staber, MD PhD, Christoph Kornauth, Ines Garces de los Fayos Alonso, Wilhelm Woessmann, MD, Wolfram Klapper, Sabine Lagger, Ana-Iris Schiefer, Cathrin Skrabs, Olaf Merkel, PhD, Marius E Mayerhoefer, Richard Greil, MD, Ingrid Simonitsch-Klupp, MD, Lukas Kenner, MD, Ulrich Jaeger, MD

Blood (2019) 134 (Supplement_1): 4037.

https://doi.org/10.1182/blood-2019-129955

Published: 2019

Journal Articles

Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinases Exerts Synergistic Effect Against Chronic Myeloid Leukemia Cells

Sylwia Flis, Ewelina Bratek, Tomasz Chojnacki, Marlena Piskorek, Tomasz Skorski, MD PhD

Blood (2019) 134 (Supplement_1): 4143.

https://doi.org/10.1182/blood-2019-129093

Published: 2019

Journal Articles

GSK1838705a, an IGF-1R/ALK Inhibitor, Overcomes Resistance to Crizotinib in ALK-Positive ALCL

Wenyu Shi, Jian-Yong Li, MD PhD

Blood (2019) 134 (Supplement_1): 4069.

https://doi.org/10.1182/blood-2019-130063

Published: 2019

Journal Articles

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Mehrdad Mobasher, MD MPH, Richard A. Miller, MD, James W. Janc, PhD, Long Kwei, PhD, Joseph J. Buggy, PhD, Gabriel Luciano, Anahita Mohammady, PharmD, Won Seog Kim, MD PhD, Youn H. Kim, MD, Michael S. Khodadoust, MD PhD, Steven M. Horwitz, MD, Dejan Radeski, MBBS, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4030.

https://doi.org/10.1182/blood-2019-124958

Published: 2019

Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA

Blood (2019) 134 (Supplement_1): 2570.

https://doi.org/10.1182/blood-2019-130898

Published: 2019

Journal Articles

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Roman Generalov, Sania Gilani, Francesco Bertoni, MD, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2019) 134 (Supplement_1): 2574.

https://doi.org/10.1182/blood-2019-123287

Published: 2019

Journal Articles

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Jacqueline S Garcia, MD, Helen I. Gandler, Geoffrey Fell, MS, Ashlee J. Fiore, Donna S Neuberg, ScD, Adrienne Anderson, Kelsey O'Day, Marlise Luskin, MDMS, Martha Wadleigh, MD, Eric S. Winer, MD, Ilene Galinsky, Daniel J. DeAngelo, MD, David A. Frank, MD PhD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 2549.

https://doi.org/10.1182/blood-2019-126224

Published: 2019

Journal Articles

Clinical ALK5 Inhibitor, Vactosertib, Reverses TGFβ-1 Stimulated Smad-2 Driven Ineffective Hematopoiesis in MDS

Srinivas Aluri, Kimo Bachiashvili, MD, Anjali Budhathoki, MD, Tushar D Bhagat, PhD, Gaurav S Choudhary, PhD, Shanisha Gordon, Nandini Ramachandra, Kith Pradhan, PhD, Shahina Maqbool, Aditi Shastri, MD, Jung Im Huh, Sunjin Hwang, Kim Seong-Jin, PhD, Hui Zhang, Britta Will, PhD, Amittha Wickrema, PhD, Ulrich G. Steidl, MD PhD, Amit Verma, MBBS

Blood (2019) 134 (Supplement_1): 2990.

https://doi.org/10.1182/blood-2019-127561

Published: 2019

Journal Articles

Targeting the Plasma Cell Specific Purine Metabolic Enzyme, AMPD1, Induces Multiple Myeloma Cell Death Accompanying NAD Depletion

Yawara Kawano, MD PhD, Takayuki Sasano, Saki Kushima, Yuki Inada, Nao Nishimura, MD, Hiroyuki Hata, MD PhD, Masao Matsuoka, MD PhD

Blood (2019) 134 (Supplement_1): 3097.

https://doi.org/10.1182/blood-2019-125756

Published: 2019

Journal Articles

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Blood (2019) 134 (Supplement_1): 2950.

https://doi.org/10.1182/blood-2019-126035

Published: 2019

Journal Articles

Pre-Emptive Tyrosine Kinase-Inhibitor Intervention Based on BCR/ABL1 Monitoring in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Allo-HSCT: Two Independent Observational Cohort Study

Liu Hui, MD, Li Xuan, MD, Ren Lin, MD, Lan Deng, MD PhD, Fen Huang, MD, Zhiping Fan, MD, Danian Nie, MD, Xudong Li, Xinquan Liang, Dan Xu, Yu Zhang, Na Xu, MD, Jieyu Ye, MD PhD, Hua Jin, Dongjun Lin, MD, Liping MA, MD, Jing Sun, MD, Xiaojun Huang, MD, Qifa Liu, MD

Blood (2019) 134 (Supplement_1): 3303.

https://doi.org/10.1182/blood-2019-126901

Published: 2019

Journal Articles

Real-World Utilization of Midostaurin Among Patients with Acute Myeloid Leukemia (AML)

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Jonathan K. Kish, PhD MPH, Dhruv Chopra, MS, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 5135.

https://doi.org/10.1182/blood-2019-130671

Published: 2019

Journal Articles

Identification of a Pharmacodynamic Biomarker for SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor for Acute Myeloid Leukemia, and Its Implementation in the First-in-Human Study CLI24-001

Andrea Tomirotti, PhD, Giuseppe Merlino, Alessio Fiascarelli, PhD, Simone Baldini, MD, Alessia Tagliavini, Elisa Borella, Milena Mazan, PhD, Krzysztof Brzózka, PhD, Alessandro Bressan, Andrea Pellacani, PhD MD, Massimiliano Salerno, Monica Binaschi, PhD, Daniela Bellarosa

Blood (2019) 134 (Supplement_1): 5087.

https://doi.org/10.1182/blood-2019-124800

Published: 2019

Journal Articles

The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia

Usva Zafar, BSc, Mohammed Yusuf, PhD, Rikhia Chakraborty, PhD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA, Afsar Ali Mian, BSc, MPhil, PhD

Blood (2019) 134 (Supplement_1): 5196.

https://doi.org/10.1182/blood-2019-131694

Published: 2019

Journal Articles

Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia

Grazia Fazio, Silvia Bresolin, Claudia Saitta, Daniela Silvestri, Elena Vendramini, Chiara Palmi, Silvia Rigamonti, Marta Galbiati, Manuel Quadri, Stefano Mecca, Angela Maria Savino, Michela Bardini, Andrea Grioni, Maria Grazia Valsecchi, PhD, Geertruy te Kronnie, Andrea Biondi, MD, Giovanni Cazzaniga, PhD

Blood (2019) 134 (Supplement_1): 745.

https://doi.org/10.1182/blood-2019-128509

Published: 2019

NARROW

Kinase inhibitors in CLL: drawing the roadmap

Targeting Critical Kinases and Anti-Apoptotic Molecules Overcomes Steroid Resistance in Infant MLL-Rearranged Leukemia

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinases Exerts Synergistic Effect Against Chronic Myeloid Leukemia Cells

GSK1838705a, an IGF-1R/ALK Inhibitor, Overcomes Resistance to Crizotinib in ALK-Positive ALCL

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Clinical ALK5 Inhibitor, Vactosertib, Reverses TGFβ-1 Stimulated Smad-2 Driven Ineffective Hematopoiesis in MDS

Targeting the Plasma Cell Specific Purine Metabolic Enzyme, AMPD1, Induces Multiple Myeloma Cell Death Accompanying NAD Depletion

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Pre-Emptive Tyrosine Kinase-Inhibitor Intervention Based on BCR/ABL1 Monitoring in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Allo-HSCT: Two Independent Observational Cohort Study

Real-World Utilization of Midostaurin Among Patients with Acute Myeloid Leukemia (AML)

Identification of a Pharmacodynamic Biomarker for SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor for Acute Myeloid Leukemia, and Its Implementation in the First-in-Human Study CLI24-001

The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia

Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only